A 24-year-old Aboriginal woman from a remote community has a history of acute rheumatic fever with established rheumatic heart disease. She has been on secondary prophylaxis with intramuscular benzathine benzylpenicillin 1.2 million units every 4 weeks since age 12. She has had no recurrent episodes and is now planning to move to an urban area. What is the most appropriate recommendation regarding prophylaxis at this stage?